Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 55/100

Failure Rate

20.4%

10 terminated/withdrawn out of 49 trials

Success Rate

79.2%

-7.3% vs industry average

Late-Stage Pipeline

16%

8 trials in Phase 3/4

Results Transparency

61%

23 of 38 completed trials have results

Key Signals

23 with results8 terminated

Enrollment Performance

Analytics

Phase 2
21(43.8%)
Phase 1
15(31.3%)
Phase 3
7(14.6%)
N/A
4(8.3%)
Phase 4
1(2.1%)
48Total
Phase 2(21)
Phase 1(15)
Phase 3(7)
N/A(4)
+1 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (49)

Showing 20 of 49 trials
NCT07494045Phase 2Not Yet Recruiting

Pharmacokinetics, Pharmacodynamics, Safety and Tolerability Evaluation of CTAP101 Extended-release Capsules in Pediatric Participants

Role: lead

NCT05543928Phase 3Terminated

Phase 3 Safety and Efficacy Study of CTAP101 Extended-release Capsules in Children With Secondary Hyperparathyroidism

Role: lead

NCT02968004Phase 3Completed

Safety and Efficacy Phase 3 Study of Long-acting hGH (MOD-4023) in Growth Hormone Deficient Children

Role: lead

NCT02500316Phase 2Completed

Long Term Follow up Study of Long-acting hGH (MOD-4023) in Growth Hormone Deficient Children

Role: lead

NCT03602261Phase 2Terminated

Safety, Efficacy, PK and PD of CTAP101 (Calcifediol) ER Capsules for SHPT in HD Patients VDI

Role: lead

NCT04551911Phase 2Completed

Safety and Efficacy of Rayaldee for Treating Mild to Moderate COVID-19

Role: lead

NCT03588884Phase 4Completed

Repeated-dose Safety, Efficacy, Pharmacokinetic and Pharmacodynamic of CTAP101, Immediate-release Calcifediol, High-dose Cholecalciferol, and Paricalcitol Plus Low-dose Cholecalciferol in Patients With Secondary Hyperparathyroidism, Chronic Kidney Disease 3-4 and Vitamin D Insufficiency

Role: lead

NCT01909479Phase 3Terminated

A Phase 3, Multicenter Study To Evaluate The Efficacy And Safety Of MOD-4023 In Adults With Growth Hormone Deficiency

Role: lead

NCT03297398Phase 2Terminated

Effects and Safety of OPK-88004 Doses in Men With Signs and Symptoms of Benign Prostatic Hyperplasia (BPH)

Role: lead

NCT03874013Phase 3Completed

Safety and Efficacy Study of MOD-4023 to Treat Children With Growth Hormone Deficiency

Role: lead

NCT03406377Phase 2Completed

Effects and Safety of OPK-88003 Dose Escalation in Type 2 Diabetes Subjects

Role: lead

NCT02188303Phase 1Terminated

A Study of LY2944876 in Healthy Japanese and Non-Japanese Participants

Role: lead

NCT02119819Phase 2Completed

A Study to Compare a New Drug for Type 2 Diabetes to Placebo and to a Treatment Already Available for Type 2 Diabetes

Role: lead

NCT02418793Phase 1Completed

A Study of a Long-Acting r-Factor 7a (Factor VIIa) in Adult Men With Hemophilia A or B

Role: lead

NCT04063644Not ApplicableCompleted

Quality of Life and Visual Acuity of Visglyc Eye Drops on Dry Eye Patients

Role: lead

NCT03762408Not ApplicableCompleted

Efficacy and Safety of a Intra-articular Injection, ENKO1, in Patients With Symptomatic Knee Osteoarthritis.

Role: lead

NCT03810664Phase 1Completed

A Clinical Study Investigating the Comparability of Somatrogon in Two Different Drug Product Presentations

Role: lead

NCT01592500Phase 2Completed

Safety and Efficacy Phase 2 Study of Long-acting hGH (MOD-4023) in Growth Hormone Deficient Children

Role: lead

NCT01791725Phase 2Completed

A 4-Week Safety Study of Oral ELND005 in Young Adults With Down Syndrome Without Dementia

Role: lead

NCT00568776Phase 2Completed

ELND005 in Patients With Mild to Moderate Alzheimer's Disease

Role: lead